Scarica l'app Stockscreener
69.53
0.51%
0.35
Dopo l'orario di chiusura:
69.54
0.01
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$69.18
Aprire:
$69.13
Volume 24 ore:
1.05M
Relative Volume:
1.98
Capitalizzazione di mercato:
$2.67B
Reddito:
-
Utile/perdita netta:
$-241.60M
Rapporto P/E:
-10.51
EPS:
-6.6167
Flusso di cassa netto:
$-201.34M
1 W Prestazione:
-0.76%
1M Prestazione:
-13.30%
6M Prestazione:
+17.58%
1 anno Prestazione:
+11.02%
Intervallo 1D:
$67.70
$69.60
Intervallo di 1 settimana:
$66.72
$72.07
Portata 52W:
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Nome
Disc Medicine Inc
Settore
Industria
Telefono
(617) 674-9274
Indirizzo
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
69.53 | 2.69B | 0 | -241.60M | -201.34M | -6.6167 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Ripresa | Stifel | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-11 | Ripresa | Raymond James | Strong Buy |
| 2025-02-27 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-22 | Iniziato | Wells Fargo | Overweight |
| 2024-04-01 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-17 | Iniziato | Raymond James | Outperform |
| 2023-04-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-21 | Iniziato | Stifel | Buy |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2023-03-23 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Disc Medicine Inc Borsa (IRON) Ultime notizie
Squarepoint Ops LLC Increases Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine (NASDAQ:IRON) Raised to "Hold" at Wall Street Zen - MarketBeat
Officer at Disc Medicine (NASDAQ: IRON) plans to sell 27,136 shares - Stock Titan
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - PR Newswire
Disc Medicine (NASDAQ:IRON) Shares Down 5%Should You Sell? - MarketBeat
The Technical Signals Behind (IRON) That Institutions Follow - Stock Traders Daily
Opaleye Management Inc. Raises Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones - Benzinga
IRON Reiterated by Wedbush -- Price Target Maintained at $100 - GuruFocus
Disc Medicine's Phase 2 rare blood cancer data; Frazier adds to public fund - Endpoints News
Form 8K Disc Medicine Inc For: 10 September By Investing.com - Investing.com South Africa
Disc Medicine reports promising DISC-3405 Phase 2 data - TipRanks
Disc Medicine's (IRON) "Outperform" Rating Reiterated at Wedbush - MarketBeat
Disc Medicine at Wells Fargo conference: two drug bets near key tests - Investing.com Canada
H.C. Wainwright reiterates Disc Medicine stock rating on trial data By Investing.com - Investing.com India
Disc Medicine reports Phase 2 DISC-3405 trial results - grafa.com
Jefferies reiterates Disc Medicine stock rating on polycythemia data By Investing.com - Investing.com Nigeria
Disc Medicine stock rating held at Outperform by BMO on trial data - Investing.com Canada
Disc Medicine reports positive phase 2 trial results for DISC-3405 By Investing.com - Investing.com South Africa
Disc Medicine (IRON) Reports Promising Phase 2 Data; Market Pric - GuruFocus
Disc Medicine reports positive phase 2 trial results for DISC-3405 - investing.com
Disc Medicine Reports Positive Initial RESTORE-PV Results for DISC-3405 in Polycythemia Vera - Quiver Quantitative
Blood-removal procedures fell from 4.0 at baseline to 0.6 after treatment - Stock Titan
Disc Medicine Investor News: If You Have Suffered Losses in - GlobeNewswire
Insider Selling: Disc Medicine (NASDAQ:IRON) Director Sells $135,052.44 in Stock - MarketBeat
Disc Medicine (NASDAQ: IRON) director sells shares under preset plan - Stock Titan
Disc Medicine at cantorfitzgerald healthcare conference: pipeline nears key tests - Investing.com Canada
Disc Medicine faces class action over alleged m... - Pluang
Legal & General Group Plc Invests $1.35 Million in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Small Disc Medicine (NASDAQ: IRON) shareholder sale planned - Stock Titan
Disc Medicine (NASDAQ: IRON) files notice to sell about $60K in stock - Stock Titan
Disc Medicine (NASDAQ: IRON) holder plans $72K stock sale - Stock Titan
Proposed $176K Disc Medicine (NASDAQ: IRON) share sale by Atlas Venture Fund X - Stock Titan
Kevin Bitterman Sells 129 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Insider Selling: Disc Medicine (NASDAQ:IRON) Director Sells $3,941,477.88 in Stock - MarketBeat
Kevin Bitterman Sells 5,203 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine (IRON) director's funds sell 54K shares in 10b5-1 trades - Stock Titan
Disc Medicine(IRON.US) Director Sells US$4.37 Million in Common Stock - Moomoo
Atlas fund plans small Disc Medicine (NASDAQ: IRON) share sale - Stock Titan
Venture fund plans Disc Medicine (IRON) share sale - Stock Titan
Disc Medicine (NASDAQ: IRON) investor plans $225K stock sale - Stock Titan
Disc Medicine (IRON) investor plans 2,339-share sale - Stock Titan
Man Group plc Takes $1.09 Million Position in Disc Medicine, Inc. $IRON - MarketBeat
The Manufacturers Life Insurance Company Takes Position in Disc Medicine, Inc. $IRON - MarketBeat
Venture fund to sell 513 Disc Medicine (NASDAQ: IRON) shares - Stock Titan
Disc Medicine (NASDAQ: IRON) investor plans Rule 144 share sale - Stock Titan
Venture backer plans Disc Medicine (NASDAQ: IRON) share sale - Stock Titan
Venture fund plans Disc Medicine (IRON) share resale - Stock Titan
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns - Stocktwits
IRON Maintained by Wedbush -- Price Target Raised to $100 - GuruFocus
Disc Medicine Inc Azioni (IRON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Disc Medicine Inc Azioni (IRON) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bitterman Kevin | Director |
Sep 11 '26 |
Option Exercise |
45.07 |
27,136 |
1,223,144 |
27,136 |
| Bitterman Kevin | Director |
Sep 11 '26 |
Sale |
70.11 |
27,136 |
1,902,505 |
0 |
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):